Clinical trial of HER2 cancer vaccine shows benefit in 45% of evaluable patients in phase 1 study

被引：0
|
作者：
Berzofsky, Jay [1 ]
Wood, Lauren [1 ]
Maeng, Hoyoung [1 ]
Trepel, Jane [1 ]
Stroncek, David [2 ]
Morris, John [3 ]
机构：
[1] NCI, NIH, Bethesda, MD 20892 USA
[2] NIH, Ctr Clin, Bethesda, MD 20892 USA
[3] Univ Cincinnati, Sch Med, Cincinnati, OH 45221 USA
来源：
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES | 2019年 / 81卷
关键词：
D O I：
10.1097/01.qai.0000557959.74614.41
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
C-105
引用
收藏
页码：38 / 38
页数：1
相关论文
共 50 条
  • [41] A prospective study to assess the clinical utility of serum HER2 extracellular domain in breast cancer with HER2 overexpression
    Nathalie Reix
    Charlotte Malina
    Marie-Pierre Chenard
    Jean-Pierre Bellocq
    Stéphanie Delpous
    Sébastien Molière
    Anthony Sevrin
    Karl Neuberger
    Catherine Tomasetto
    Carole Mathelin
    Breast Cancer Research and Treatment, 2016, 160 : 249 - 259
  • [42] Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients.
    Gurney, JM
    Hueman, MT
    Woll, MM
    Ryan, GB
    Storrer, CE
    Fisher, C
    Shriver, CD
    Ioannides, CG
    Ponniah, S
    Peoples, GE
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 184S - 184S
  • [43] Clinical and immunologic responses of HLA-A3+ breast cancer patients vaccinated with the HER2/neu-derived peptide vaccine, E75, in a phase I clinical trial.
    Paul, R.
    Holmes, J. P.
    Amin, A.
    Carmichael, M.
    Jama, Y. H.
    McNeill, A.
    Hueman, M. T.
    Craig, D.
    Ponniah, S.
    Peoples, G. E.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S123 - S124
  • [44] Clinical and Immunologic Responses of HLA-A3+ Breast Cancer Patients Vaccinated with the HER2/neu-Derived Peptide Vaccine, E75, in a Phase I/II Clinical Trial
    Patil, Ritesh
    Clifton, Guy T.
    Holmes, Jarrod P.
    Amin, Asna
    Carmichael, Mark G.
    Gates, Jeremy D.
    Benavides, Linda H.
    Hueman, Matthew T.
    Ponniah, Sathibalan
    Peoples, George E.
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2010, 210 (02) : 140 - 147
  • [45] Early results of a phase I clinical trial of an li-Key/Her2/neu MHC class II peptide-based vaccine in breast cancer patients.
    Mittendorf, E. A.
    Khoo, S.
    Storrer, C. E.
    Harris, K. A.
    Jama, Y. H.
    Dehqanzada, Z. A.
    Murray, J. L.
    Shriver, C. D.
    Von Hofe, E.
    Ponniah, S.
    Peoples, G. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 108S - 108S
  • [46] A Phase I Trial of the HER2 Exon 20 Inhibitor, BI 1810631, In Patients With Advanced Solid Tumors With HER2 Aberrations
    Opdam, F.
    Heymach, J.
    Barve, M.
    Gibson, N.
    Sadrolhefazi, B.
    Serra, J.
    Yamamoto, N.
    Yoh, K.
    Wu, Y. -L.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S421 - S422
  • [47] The Clinical Benefit and Safety of Boosting the HER2 Peptide Vaccine (GP2+GM-CSF) in the Adjuvant Setting to Prevent Breast Cancer Recurrence
    Schneble, E.
    Berry, J. S.
    Trappey, A. F.
    Hale, D. F.
    Vreeland, T. J.
    Sears, A.
    Clifton, G. T.
    Ponniah, S.
    Papamichael, M.
    Perez, S.
    Peoples, G. E.
    Mittendorf, E.
    ANNALS OF SURGICAL ONCOLOGY, 2014, 21 : S45 - S46
  • [48] Final Analysis Shows GP2 Immunotherapy Vaccine Induces 100% DFS Rate for Patients With HER2 3+Breast Cancer
    Mauro, Gina
    ONCOLOGY-NEW YORK, 2021, 35 (02): : 90 - 90
  • [49] Early trial shows promise for a DC vaccine against HER2-positive breast cancer
    不详
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2017, 13 (02) : 251 - 251
  • [50] Immune response assessment in a phase II trial of AE37 HER2 peptide vaccine
    Hale, Diane F.
    Vreeland, Timothy J.
    Dabney, Raetasha S.
    Clifton, G. Travis
    Sears, Alan K.
    Pappou, Efi
    Anastasopoulou, Eleftheria
    Ardavanis, Alexandros
    Ponniah, Sathibalan
    Papamichail, Michael
    Perez, Sonia
    Shumway, Nathan
    Peoples, George E.
    Mittendorf, Elizabeth
    CANCER RESEARCH, 2012, 72
12345